✨ Free AI Report
Abivax S.A.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Research Preview Abivax S.A.
Research Preview

Abivax S.A.: Business Overview, Financials & Competitive Analysis

Abivax's lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. The company is a clinical-stage biotechnology company focused on ...

Analyst-debate audio for Abivax S.A.

AskCyborg analysts argue the bull and bear cases for Abivax S.A. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Abivax S.A. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below
6/ 10Mixed

Cyborg Score thesis

Mid-stage biotech with differentiated immunology approach but elevated clinical risk following recent Phase 3...

Read the full analyst-debate transcript →
Industry Immunology Drugs
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Abivax S.A. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Abivax S.A. Overview

Pro stress-test →

Abivax's lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. The company is a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases.

Strategic Profile

Pro stress-test →

Phase 3 obefazimod maintenance data was released in early June 2026, causing significant stock volatility as traders reset expectations. The company raised approximately $400 million in a public offering (July 2025), demonstrating investor confidence in advancing development programs.

Competitive Landscape

Pro stress-test →

Abivax competes in the crowded inflammatory bowel disease (IBD) therapeutic space against established biologics (TNF inhibitors, integrin antagonists, JAK inhibitors) and emerging small-molecule competitors. The company's differentiated miR-124 mechanism positions it as an alternative to conventional immunosuppressive approaches, but approval will depend on Phase 3 efficacy and safety profile relative to standard-of-care treatments.

Industry Context

Abivax S.A. operates in Immunology Drugs.

Key facts

Founded: 2012 · Headquarters: Paris, France · Employees: N/A · Revenue: $0 · Market cap: N/A

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Abivax S.A..

+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

Get alerted when Abivax S.A. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

TNF Inhibitors (Remicade, Humira, Simponi)Established biologics for IBD treatment→Ozanimod (Zeposia)S1P receptor modulator for UC and Crohn's disease→Upadacitinib (Rinvoq)JAK inhibitor for IBD→

Compare Abivax S.A. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Abivax S.A. operates in Immunology Drugs. See how the rest of the sector scores on the Cyborg framework.

Browse Immunology Drugs research →
NEW · MCP server

Ask your AI assistant about Abivax S.A.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Abivax S.A. and its top competitor on Cyborg Score”
“What did Abivax S.A. do this quarter?”
“Is Abivax S.A. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com (you must copy support@askcyborg.com) · Terms of Service

Frequently asked questions

What does Abivax S.A. do?+
Abivax's lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. The company is a clinical-stage biotechnology company focused on ...
What is Abivax S.A.'s Cyborg Score?+
Abivax S.A. has a Cyborg Score of 6/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Abivax S.A.'s main competitors?+
Named competitors include TNF Inhibitors (Remicade, Humira, Simponi), Ozanimod (Zeposia), Upadacitinib (Rinvoq). The full competitive landscape is in the AskCyborg report.
How can I get the full Abivax S.A. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Abivax S.A. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Abivax S.A. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.